NFYS vs. ENGN, DHHC, SBEA, NETD, ENPC, CDRO, IPXX, XPAX, KAII, and LGVC
Should you be buying Enphys Acquisition stock or one of its competitors? The main competitors of Enphys Acquisition include enGene (ENGN), DiamondHead (DHHC), SilverBox Engaged Merger Corp I (SBEA), Nabors Energy Transition Corp. II (NETD), Executive Network Partnering (ENPC), Codere Online Luxembourg (CDRO), Inflection Point Acquisition Corp. II (IPXX), Zalatoris II Acquisition (XPAX), Kismet Acquisition Two (KAII), and LAMF Global Ventures Corp. I (LGVC).
Enphys Acquisition (NYSE:NFYS) and enGene (NASDAQ:ENGN) are both small-cap unclassified companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
enGene's return on equity of 0.00% beat Enphys Acquisition's return on equity.
enGene received 7 more outperform votes than Enphys Acquisition when rated by MarketBeat users.
50.9% of Enphys Acquisition shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 44.7% of Enphys Acquisition shares are held by company insiders. Comparatively, 13.7% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Enphys Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
In the previous week, enGene had 26 more articles in the media than Enphys Acquisition. MarketBeat recorded 26 mentions for enGene and 0 mentions for Enphys Acquisition. Enphys Acquisition's average media sentiment score of 0.00 beat enGene's score of -0.09 indicating that Enphys Acquisition is being referred to more favorably in the media.
enGene has a consensus price target of $34.40, suggesting a potential upside of 291.35%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Enphys Acquisition.
Summary
enGene beats Enphys Acquisition on 6 of the 11 factors compared between the two stocks.
Get Enphys Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NFYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enphys Acquisition Competitors List
Related Companies and Tools
